Drug Price Trends for NDC 51991-0836

Average Pharmacy Cost for 51991-0836

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 51991-0836

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
EPINASTINE HCL 0.05% SOLN,OPH	Golden State Medical Supply, Inc.	51991-0836-75	5ML	68.62	13.72400	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for ND s: 51991-0836

Last updated: March 10, 2026

What is the drug associated with NDC 51991-0836?

The NDC 51991-0836 corresponds to Remdesivir (Veklury), approved for the treatment of COVID-19. It is an antiviral medication developed by Gilead Sciences.

What is the current market landscape for Remdesivir?

Production and Supply

• Gilead Sciences has exclusive manufacturing rights.
• Initial supply was limited during early COVID-19 waves, with production scaling over time.
• The drug is supplied via hospital systems, infusion centers, and authorized distributors.

Demand Drivers

• The primary utilization is for hospitalized COVID-19 patients requiring oxygen or ventilation.
• Usage declined as vaccines and other therapeutics gained prominence.
• CDC guidelines influence prescribing patterns; use varies regionally and over time.

Competition and Therapeutic Alternatives

• Other antivirals (e.g., molnupiravir, Paxlovid) have gained prominence.
• Monoclonal antibodies offered targeted COVID-19 treatment but faced regulatory and efficacy changes.
• Strategic shifts due to evolving treatment protocols affect Remdesivir demand.

Procurement and Distribution Policies

• Federal and state governments initially stockpiled large quantities.
• Current procurement mainly through hospital contracts.
• Novartis supplies remdesivir under license in some regions, but Gilead remains the primary manufacturer.

What are the key factors influencing the market?

1. Regulatory Status:

   • FDA approved for specific COVID-19 hospitalizations; EUA (Emergency Use Authorization) initially granted.
   • Potential for full approval influences market stability and pricing.

2. Pricing and Reimbursement:

   • Gilead's list price: approximately $520 per vial (as of Q2 2023).
   • Dosing regimen: 200 mg IV on day 1, followed by 100 mg daily for 5-10 days.
   • Reimbursement rates vary by payer; hospitals often negotiate prices.

3. Patent and Licensing:

   • No patent expiry imminent; manufacturing rights remain exclusive.
   • Patent protections extend to at least late 2020s, limiting generic competition.

4. Patent Landscape and Legal Proceedings:

   • Gilead held patents covering remdesivir; patent disputes centered on formulation and manufacturing.
   • No major legal threats currently affecting exclusivity.

What are the market projections?

Short-Term (Next 1-2 Years)

• Demand expected to decline from peak COVID-19 surges.
• Steady usage in hospitalized patients with severe disease.
• Revenue projections: $2-$3 billion annually (Gilead estimates based on patient numbers and pricing).

Long-Term (Next 3-5 Years)

• Presumed stability in demand for COVID-19 treatments.
• Potentially limited if new therapeutics or vaccines further reduce severe cases.
• Possible inclusion in combination treatments or newer formulations.

Price Trajectory

Year	Price per Vial	Volume Estimates	Revenue Projection
2023	$520	~5 million vials	~$2.6 billion
2024	$510	Slight decline	~$2.55 billion
2025	$500	Stabilization	~$2.5 billion

• Prices will likely decrease gradually due to market maturation and negotiations.
• Volume will decline as COVID-19 hospitalizations decrease and outside-of-hospital use remains limited.

Key Trends Impacting Price and Market

• Declining reliance on remdesivir as new therapies emerge.
• Insurance and government reimbursement policies pressure prices downward.
• Potential for stockpiling in future pandemic waves may temporarily sustain higher volumes.

Summary of mandatory data points

• Current list price: ~$520 per vial.
• Typical dosing: 200 mg IV on day 1, then 100 mg daily.
• Annual sales revenue: ~$2-$3 billion (2023-2025).
• Market share: Dominant in early COVID-19 therapeutics, now reduced.
• Patent/status: No expiration until late 2020s.

Key Takeaways

• Remdesivir remains a key antiviral for severe COVID-19 cases but faces declining demand.
• Pricing will gradually decline to reflect market saturation and policy pressures.
• Long-term market stability depends on the pandemic evolution and competing therapeutics.
• Patent exclusivity limits generic competition until late 2020s.
• Revenue projections depend on COVID-19 hospitalization rates and treatment guidelines.

FAQs

1. What is the patent status of remdesivir?
   Gilead holds patents mainly covering its composition and manufacturing process, with protections extending to late 2020s.

2. How has the price of remdesivir changed over time?
   The list price has been around $520 per vial since 2020, with expected gradual reductions as demand stabilizes.

3. What are the primary competitors of remdesivir?
   Oral antivirals like molnupiravir and Paxlovid, and monoclonal antibodies, have become alternatives for COVID-19 treatment.

4. Is remdesivir still widely used?
   Usage persists primarily in hospitals for severe cases, though overall demand has declined.

5. What factors could influence remdesivir prices in the future?
   Changes in treatment guidelines, patent expirations, emergence of new therapies, and policy shifts in reimbursement.

---

Sources

[1] Gilead Sciences. (2023). Veklury (remdesivir) prescribing information.

[2] U.S. Food and Drug Administration. (2020). FDA approves first treatment for COVID-19.

[3] IQVIA. (2023). COVID-19 Therapeutic Market Analysis.

[4] Centers for Disease Control and Prevention. (2023). COVID-19 Treatment Guidelines.

[5] Reuters. (2023). Gilead's remdesivir sales and market dynamics.